Hidradenitis suppurativa (HS) is an inflammatory skin disease that affects roughly 1% of Europeans. It is characterized by painful abscesses, boils, cysts, and malodorous, pus-filled lesions in intertriginous regions ([@B1], [@B2]). It can follow autosomal dominant inheritance in some families, and mutations have been reported ([@B3]) in the gamma-secretase genes Presenilin-1 (*PSEN1*), Presenilin Enhancer-2 (*PSENEN*), and Nicastrin (*NCSTN*) in a minority (\<7%) of cases. The remaining cohort are presumed to be sporadic or driven by other, as yet unidentified mutations. Nevus comedonicus (NC) is a rare (prevalence 1:45,000--1:100,000) epidermal nevus comprising of a group of dilated hair follicle openings filled with plugs of brownish-black oxidized keratin ([@B4]). It is usually localized on the head and neck and was initially described as "localized acne" ([@B5]). If it occurs as a part of the nevus comedonicus syndrome (NCS) ([@B6]), it can be generalized and form linear streaks. HS-like lesions have been observed in NCS ([@B7]). In some cases of NC, a somatic mutation in fibroblast growth factor-receptor gene 2 (*FGFR2*) has been identified, namely the Ser252Trp missense mutation ([@B5]). FGFR2 is expressed in keratinocytes, hair follicles, and sebaceous glands and has been implicated to induce hypercornification and comedogenesis ([@B8]). Germline *FGFR2* mutations are also associated with acne, as seen in dominant Apert syndrome ([@B9]) (also comprising craniosynostosis, epiphyseal closure, and syndactyly) ([@B10], [@B11]). When occurring as a mosaic, the acne lesions follow Blaschko's lines ([@B12]), the pattern of embryological cell development and proliferation. In a recent case, a postzygotic mosaicism was found in exon 4 of *FGFR2* (c.758C\>G, p.Pro253Arg) in low copy number. A similar mosaicism was also found in two other patients in p.Ser252Trp of exon 4 ([@B8]).

A 49-year-old male construction worker presented with a 29-year history of multiple abscesses in his buttock, inguinal, and axillary regions (Figure [1](#F1){ref-type="fig"}) and a history of severe post-pubertal acne conglobate. His back was studded with innumerable large comedones not unlike those seen in NC, however rather more spread out (Figure [1](#F1){ref-type="fig"}A), and with significant scarring. His condition had proved resistant to treatment with topical and systemic antibiotics, dapsone, retinoids, including acitretin and isotretinoin, zinc supplements and PUVA. Treatment with infliximab did have an effect on the inflammatory components; however, it was minimal and ultimately unsuccessful. Surgical interventions included excision of the left axilla and shoulder region and a transposition flap and excision of a pilonidal sinus.

![**Widespread abscesses present in 49-year-old male patient**. **(A)** Back of patient showing grouped comedones and hidradenitis suppurativa (HS) scars. **(B)** Inguinal scars. **(C)** Close-up of open HS lesions.](fmed-04-00016-g001){#F1}

The patient is an orphan. It is known that several other people in his family including his father and brother had suffered from the same condition with different intensities; however, there is no contact between the patient and family. Requests to collect samples from family members were denied by the patient. Suspecting a potential genetic origin ([@B13]), we therefore performed whole exome sequencing on blood-derived DNA. A search for rare, deleterious mutations revealed that there was no such mutation present in any of the known HS-associated genes. However, a rare missense mutation in the *FGFR2* gene was found in exon 5 (c.G492C, p.K164N, see Table [1](#T1){ref-type="table"}). This mutation is predicted ([@B14]) to have pathological consequence on the protein by several prediction algorithms, namely SIFT ("deleterious," lowest score 0), PolyPhen ("probably damaging," highest score 1), LoFtool ("probably damaging," 0.00179), Condel ("deleterious," 1.00), CADD (17.05), and SNPs&Go (73% probability). MutPred resulted in 63% probability for "damaging," and predicted ([@B15]) molecular features of the mutation are loss of methylation at K164 (*P* = 0.0069), loss of ubiquitination at K164 (*P* = 0.0081), loss of solvent accessibility (*P* = 0.0371), and loss of MoRF binding (not significant, *P* = 0.0575) as well as gain of sheet (not significant, *P* = 0.1451).

###### 

**Fibroblast growth factor-receptor gene 2 (FGFR2) mutation identified in the patient**.

  Chr           Pos                 Ref                 Alt                           Exon             Mutation           MAF in 1KG, EVS, ExAC
  ------------- ------------------- ------------------- ----------------------------- ---------------- ------------------ -----------------------
  10            123310936           C                   G                             exon5            c.G492C, p.K164N   0.00
  **SIFT**      **PolyPhen**        **Condel**          **LoFtool**                   **SNPs&Go**      **MutPred**        **CADD**
  deleterious   probably_damaging   deleterious (1.0)   probably damaging (0.00179)   Disease (0.73)   Disease (0.626)    17.1

Discussion {#S1}
==========

In a patient with clinical features reminiscent of NCS, we found a new, rare heterozygous missense mutation in *FGFR2*, the gene for the keratinocyte growth factor (KGF) receptor. FGFR2, also known as CD332, was cloned in 1990 ([@B16]) and soon found to be the receptor for KGF. It has an extracellular part constructed of three immunoglobulin domains, a lipophilic transmembrane part, and a tyrosine kinase that extends in the cytoplasm. Fibroblast growth factors (FGF) can bind the extracellular domain and thus activate the tyrosine kinase. This leads to cell division and differentiation. The isoform found in ectodermal tissues such as the skin is the FGFR2IIIb, also known as the KGF receptor. It binds FGF-7 and 10, also known as KGF 1 and 2, as well as FGF-1, -3, -22. Keratinocyte growth factors are potent mitogens for many epithelial cell types but lack detectable activity on fibroblasts or endothelial cells.

Germline mutations in *FGFR2* underlie various craniosynostosis syndromes (Table [2](#T2){ref-type="table"}), and somatic mutations in the same gene have been reported in NC ([@B5]) and nevoid acne ([@B9]). We report a germline mutation in *FGFR2* that may contribute to explaining a generalized, rather than mosaic, NC-like, acneiform phenotype with additional features of HS. As documented above, the disease proved highly treatment resistant, which is a common feature in NC. FGFR inhibitors, which may directly address the genetically driven pathogenesis, exist but have not been reported in this context.

###### 

**Diseases caused by FGFR2 mutations**.

  Location   Phenotype                                                                         Phenotype MIM number   Inheritance   Phenotype mapping key
  ---------- --------------------------------------------------------------------------------- ---------------------- ------------- -----------------------
  10q26.13   Antley--Bixler syndrome without genital anomalies or disordered steroidogenesis   207410                 AR            3
  10q26.13   Apert syndrome                                                                    101200                 AD            3
  10q26.13   Beare-Stevenson cutis gyrata syndrome                                             123790                 AD            3
  10q26.13   Bent bone dysplasia syndrome                                                      614592                 AD            3
  10q26.13   Craniofacial-skeletal-dermatologic dysplasia                                      101600                 AD            3
  10q26.13   Craniosynostosis, non-specific                                                                                         3
  10q26.13   Crouzon syndrome                                                                  123500                 AD            3
  10q26.13   Gastric cancer, somatic                                                           613659                               3
  10q26.13   Jackson--Weiss syndrome                                                           123150                 AD            3
  10q26.13   LADD syndrome                                                                     149730                 AD            3
  10q26.13   Pfeiffer syndrome                                                                 101600                 AD            3
  10q26.13   Saethre--Chotzen syndrome                                                         101400                 AD            3
  10q26.13   Scaphocephaly and Axenfeld-Rieger anomaly                                                                NA            3
  10q26.13   Scaphocephaly, maxillary retrusion, and mental retardation                        609579                 NA            3
  10q26.13   Nevus comedonicus                                                                 --                     Somatic       none

As the patient is a foundling, we could not determine the presence of the mutation in the rest of the family and were unable to obtain material for tissue expression studies. All available algorithms unanimously predict impaired protein function as a consequence of this mutation but follow-up studies, identifying further similar cases, are warranted to confirm this genotype--phenotype correlation. HS is a phenotypically heterogeneous condition, and ongoing genetic investigation represents one important way of classifying subtypes and related conditions.

In summary, we have identified a germline mutation in *FGFR2* in a patient exhibiting features of generalized comedones and HS. Ongoing screening and functional interrogation of this group has the potential to further characterize the related phenotype and identify novel therapeutic targets.

Written informed consent was obtained from the patient to perform genetic analysis on the blood and to publish the resulting study.
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